Docetaxel, cisplatin and 5-fluorouracil as initial therapy for patients with advanced gastric cancer
SU Dan
ZHANG Ting-ting
WANG Li-jie
BAI Li
Abstract：Objective To evaluate the efficacy and tolerability of paclitaxel combined with cisplatin and fluorouracil (DCF) regimen as first line therapy for advanced gastric cancer (AGC).Methods Data from sisty-one patients treated with docetaxel with a dose of 75 mg/m2 on Day 1,cisplatin with a dose of 75 mg/m2 on Day 1 and infusional 5-fluorouracil with a dose of 750 mg/( m2 · day) on Days 1 to 5 (DCF) regimen.All the cases received DCF for at least 3 cycles and efficacy can be evaluated as well.Results The response rate (RR) was 34.4％ and the disease control rate (DCR) was 82.0％.The median progression-free time(mPFS) and median overall survival time (OS) were 6.2 and 10.1 months respectively.72.1％ of cases developed treatment-related grade 3 or 4 granulocytopenia.Conclusion DCF regimen is effective but with high hematologic toxicity rate and it can be a promising therapy for AGC cases.
Keywords：Stomach neoplasmsAntineoplastic combined chemotherapy protocolsDocetaxelCisplatinFluorouracil
Publication Date：2012-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)